620 related articles for article (PubMed ID: 33948911)
1. Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial.
Boinpally R; Spaventa J; Chen K; Butler M
Clin Drug Investig; 2021 Jun; 41(6):557-567. PubMed ID: 33948911
[TBL] [Abstract][Full Text] [Related]
2. Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial.
Boinpally R; Jakate A; Butler M; Periclou A
Pain Manag; 2022 May; 12(4):499-508. PubMed ID: 34898273
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Safety of Coadministered Atogepant and Topiramate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study.
Boinpally R; McGeeney D; Borbridge L; Trugman J
Clin Pharmacol Drug Dev; 2023 Oct; 12(10):1013-1021. PubMed ID: 37210713
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
[TBL] [Abstract][Full Text] [Related]
5. Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
Blumenfeld AM; Boinpally R; De Abreu Ferreira R; Trugman JM; Dabruzzo B; Ailani J; Lipton RB
Headache; 2023 Mar; 63(3):322-332. PubMed ID: 36602199
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Safety of Atogepant Co-administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study.
Boinpally R; Borbridge L; Wangsadipura V
Clin Pharmacol Drug Dev; 2024 May; ():. PubMed ID: 38702918
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial.
Goadsby PJ; Dodick DW; Ailani J; Trugman JM; Finnegan M; Lu K; Szegedi A
Lancet Neurol; 2020 Sep; 19(9):727-737. PubMed ID: 32822633
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the pharmacokinetic interactions and safety of atogepant coadministered with esomeprazole.
Boinpally R; Butler M; Rojo J; Borbridge L; Wangsadipura V; Papinska A
Pain Manag; 2023 Jun; 13(6):351-361. PubMed ID: 37424270
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of Bafiertam® (monomethyl fumarate) versus Vumerity® (diroximel fumarate).
Rousseau FS; Wang L; Sprague TN; Lategan TW; Berkovich RR
Mult Scler Relat Disord; 2023 Feb; 70():104500. PubMed ID: 36645997
[TBL] [Abstract][Full Text] [Related]
10. Investigation of the Effect of Lasmiditan on the Pharmacokinetics of P-Glycoprotein and Breast Cancer Resistance Protein Substrates.
Luffer-Atlas D; Wilbraham D; Posada MM; Landry J; Tsai M; Pearlman EM
J Clin Pharmacol; 2024 Jan; 64(1):94-102. PubMed ID: 37566903
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Interactions and Tolerability of Rosuvastatin and Ezetimibe: A Randomized, Phase 1, Crossover Study in Healthy Chinese Participants.
Wang L; Luan Y; Jia C; Xie X; Zhang Z; Xie X; Wang Q; Hu C; Xie F; Abdel-Moneim M; Hovsepian L; Zhao Z; Yang N; Hou J
Eur J Drug Metab Pharmacokinet; 2023 Jan; 48(1):51-62. PubMed ID: 36437383
[TBL] [Abstract][Full Text] [Related]
12. Once-daily oral atogepant for the long-term preventive treatment of migraine: Findings from a multicenter, randomized, open-label, phase 3 trial.
Ashina M; Tepper SJ; Reuter U; Blumenfeld AM; Hutchinson S; Xia J; Miceli R; Severt L; Finnegan M; Trugman JM
Headache; 2023 Jan; 63(1):79-88. PubMed ID: 36651532
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib-tramadol co-crystal: A Randomized 4-Way Crossover Comparative Bioavailability Study.
Cebrecos J; Carlson JD; Encina G; Lahjou M; Sans A; Sust M; Vaqué A; Morte A; Gascón N; Plata-Salamán C
Clin Ther; 2021 Jun; 43(6):1051-1065. PubMed ID: 34167827
[TBL] [Abstract][Full Text] [Related]
14. A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial.
Boinpally R; McNamee B; Yao L; Butler M; McGeeney D; Borbridge L; Periclou A
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1099-1107. PubMed ID: 33942560
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza
Mai G; Fan L; Li M; Zhang P; Gan C; Huang Q; Shentu J
Front Pharmacol; 2020; 11():610880. PubMed ID: 33584289
[No Abstract] [Full Text] [Related]
16. Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.
Rizzoli P; Marmura MJ; Robblee J; McVige J; Sacco S; Nahas SJ; Ailani J; De Abreu Ferreira R; Ma J; Smith JH; Dabruzzo B; Ashina M
J Headache Pain; 2024 Mar; 25(1):35. PubMed ID: 38462625
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP3A4 inhibition/induction and OATP inhibition on the pharmacokinetics of atogepant in healthy adults.
Boinpally R; Chen W; McGeeney D; Trugman JM
Pain Manag; 2023 Aug; ():. PubMed ID: 37650778
[TBL] [Abstract][Full Text] [Related]
18. Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide.
Urva S; Quinlan T; Landry J; Ma X; Martin JA; Benson CT
Clin Pharmacokinet; 2022 Jul; 61(7):1057-1067. PubMed ID: 35674880
[TBL] [Abstract][Full Text] [Related]
19. Effects of Food on the Pharmacokinetic Properties and Mass Balance of Henagliflozin in Healthy Male Volunteers.
Chen ZD; Chen Q; Zhu YT; Zhang YF; Zhan Y; Chen XF; Liang X; Jia JY; Yu C; Liu HY; Zou JJ; Liu YM; Zhong DF
Clin Ther; 2021 Sep; 43(9):e264-e273. PubMed ID: 34366153
[TBL] [Abstract][Full Text] [Related]
20. Effect of a moderate CYP3A inducer efavirenz on the pharmacokinetics of fuzuloparib: An open-label, fixed sequence study in Chinese healthy male subjects.
Hu L; Dou T; Sun Q; Tang L; Cai M; Qian W; Wang H
Invest New Drugs; 2023 Apr; 41(2):276-283. PubMed ID: 36800130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
